The exact mechanisms by which T cells contribute to MS progression are not known. Recently, the results of cross-sectional studies suggested seasonal variation of both interferon (IFN)-␥ production and the number of active MRI lesions in MS. Objective: To investigate whether seasonal fluctuations of IFN-␥ and active MRI lesions could be confirmed and whether any correlations could be detected. Methods: Data were analyzed from a group of 28 MS patients in whom detailed longitudinal monitoring of both immune function and MRI measurements had taken place. Results: Significant seasonal variation was observed in T-cell activation as measured by the ability of T cells to secrete the pro-inflammatory cytokines tumor necrosis factor-␣ and IFN-␥. Maximum values were found in samples obtained during autumn. Even though clear fluctuations were observed, no significant seasonal variation could be detected in the number of active MRI lesions. Fluctuations of in vitro IFN-␥ secretion correlated weakly with changes in active MRI lesions. Conclusion: The finding of seasonal variation of immune function in serially MRI-monitored MS patients suggests an environmental role in T-cell activation.
Evidence suggests that MS is the result of a complex interplay among several genes and currently unknown environmental factors. It is clear, however, that T cell-mediated inflammatory events in the CNS of patients with MS play a role in the pathogenesis of this disease. After priming, CD4
ϩ T-helper (Th) cells can mature into functionally different subsets, which can be distinguished by their cytokine secretion profile. 1 A distinction can be made between cytokines with pro-inflammatory properties, such as interferon (IFN)-␥ and tumor necrosis factor (TNF)-␣, produced by Th1 cells, and cytokines with anti-inflammatory properties, like interleukin (IL)-4 and IL-10, produced by Th2 cells. 2 Disease activity in the initial stage of MS may be dependent on activation of Th1-type cells that is insufficiently counterbalanced by Th2-type cells. 3 There is some evidence that IFN-␥ and TNF-␣ promote disease activity in MS [4] [5] [6] [7] and that IL-4 and IL-10 attenuate the disease process. [7] [8] [9] [10] Seasonal variation in cytokines and cell-mediated immunity has been found in animal studies, 11 in healthy volunteers, 12 and in MS patients. 13 Increased IFN-␥ production has been reported in a small group of patients with progressive MS sampled in autumn and winter compared with other patients sampled in spring and summer. 13 Seasonal fluctuations have also been reported for the prevalence of clinical exacerbations in MS. However, the course of these changes in MS activity varied between different geographic regions. For example, the peak exacerbation rate in relapsingremitting MS was observed in the July through October period in northeastern Ohio, 14 in the winter and spring months in Switzerland, 15 and in the warmer months in Arizona. 16 Recently, further support for the view that season may influence (subclinical) disease activity has been provided by a study that showed a striking annual variation in the number of active MRI lesions. 17 We analyzed data from MS patients, in whom detailed longitudinal monitoring had taken place, for seasonal fluctuations of both active MRI lesions and cytokine profiles.
Patients and methods.
Patients. Analyses were carried out on 28 patients (table 1) , who were enrolled (between January and December 1993) at the Department of Neurology, VU Medical Center, Amsterdam, the Netherlands, in a multicenter, randomized, double-blind, placebocontrolled, exploratory, phase II trial of the CD4 monoclonal antibody (mAb) cM-T412. 18 Because neither T-cell proliferation and cytokine production nor the number of active MR lesions was significantly affected by treatment with anti-CD4, 19 patients from both treatment arms were included in this study.
Clinical and MRI examinations. As reported, 18 clinical examination including Expanded Disability Status Scale and MRI were performed at monthly intervals for 9 months and thereafter at months 12 and 18 (12 scans/ patient). Active lesions were defined as lesions that showed new gadopentetate dimeglumine (Gd-DTPA) enhancement on T1-weighted images and as enlarging or new lesions on T2-weighted images that were not seen on Gd-DTPA-enhanced T1-weighted images. At each visit, blood was collected (12 samples/patient during 18-month follow-up). Peripheral blood mononuclear cells (PBMC) were isolated and cryopreserved immediately. To minimize interassay variability, samples from all time points from individual patients were analyzed in one run. PBMC (25 ϫ 10 5 cells/mL) were cultured and stimulated in triplicate cultures with CD2 mAb in the presence of CD28 mAb, as previously reported. 19 Cells cultured without stimuli served as negative controls. The proliferative response (cpm) was measured after 4 days of culture by means of incorporation of [ 3 H]thymidine; 0.4 mCi/well of [ 3 H]thymidine was added 24 hours before harvesting, as previously described. 20 Cytokine production was measured using standard reagents. [19] [20] [21] [22] The in vitro cytokine secretion of PBMC (IFN-␥, TNF-␣, IL-4, and IL-10) was measured after 72 hours of culture by specific ELISA (CLB, Amsterdam, the Netherlands). Intracellular cytokine production was measured using 0.5 ϫ 10 6 cells/mL, stimulated for 4 hours with phorbol myristate acetate and ionomycin in the presence of monensin. 19 After cell surface staining with CD3-fluorescein isothiocyanate, cytoplasm was stained with biotinylated cytokine mAb (IL-4, IFN-␥) followed by streptavidin-phycoerythrin. Cells were analyzed using a fluorescence-activated cell sorter (FACS; Becton Dickinson, Sunnyvale, CA). Statistical analysis. Immunologic, clinical, and MRI data were pooled per season according to Balashov et al. 13 (March, April, May ϭ spring; June, July, August ϭ summer; September, October, November ϭ autumn; December, January, February ϭ winter). Repeated-measurement multivariate analysis of variance was used to evaluate within-subject changes over the four seasons. Anti-CD4 treatment, IV methylprednisolone (IVMP), and season of enrollment were entered as covariates. Correlations were generated using repeated-measurement regression analysis. To establish a normal distribution of the data, a log transformation was performed when data were nonnormally distributed (in vitro IL-4 and IL-10 secretion). To account for the multiple comparisons performed, a probability value of Ͻ0.01 was considered to be significant and Ͻ0.10 to indicate a trend. Clinical and MRI-documented disease activity. Even though clear fluctuations were observed, no significant seasonal variation could be detected in active MRI lesions (see tables 2 and 3) or in the number of patients experiencing clinical relapses (spring, six patients; summer, eight patients; autumn, nine patients; and winter, eight patients). Discussion. We present the first study in which a group of patients with relapsing-remitting and secondary progressive MS was analyzed longitudinally for seasonal variations in both immunologic and MRI markers of disease activity.
In agreement with other studies, an annual rhythm of pro-inflammatory cytokine secretion patterns was observed. 13 In line with our findings, seasonal variation of the IFN-␥-producing capacity, with a decrease in summertime, has been reported in healthy Finnish subjects. 12 Furthermore, Balashov et al. 13 recently reported, in a cross-sectional study, maximum IFN-␥ production in samples obtained during autumn, which is also in agreement with our findings. IFN-␥ has been directly implicated as participating in the disease process based on the observation that when given to MS patients, systemic IFN-␥ increases the frequency of clinical relapses. 4 Increased production of IFN-␥ before a clinical relapse has been demonstrated by some, 23 whereas others found no clear relation between disease activity and IFN-␥ secretion. [5] [6] [7] Although the mean number of enhancing MRI lesions clearly fluctuated, we could not confirm the existence of significant seasonal variation in active MRI lesions. Two other studies have recently addressed the issue of seasonal effects of MRI disease activity in MS. 17, 24 The first study reported that the frequency and extent of active lesions on MRI are influenced by seasonal fluctuations and are significantly higher in the first than in the second half of the year. 17 This study, however, can be criticized because longitudinal follow-up within patients was limited and variable. The second study also reported that the number of active lesions varied in the different seasons but that these variations were not statistically significant. 24 It has been argued that this absence of a statistically significant variation could be attributed to selection of patients in a very active phase of the disease (with subsequent "regression to mean") or the inclusion of patients from different geographic locations. 25 Our findings, the magnitude of fluctuations not being statistically significant, are in line with the second study, 24 even though our patient sample originates from one well-defined geographic area and covariate analysis showed that regression to the mean was not observed.
With use of repeated-measurement regression analysis, a trend for a weak negative correlation was found between changes of in vitro IFN-␥-secreting ability by PBMC and fluctuations in MRIdocumented disease activity. The fact that most regression coefficients are negative (see table 4) is No significant correlations between immune measurements and active MRI lesions over seasons were observed. However, a trend was observed for the correlation between changes of in vitro IFN-␥ secretion and active MRI lesions (r ϭ Ϫ0.354, p ϭ 0.082). The correlations were generated using repeated-measure regression analysis (quadratic trends) in 28 longitudinally studied MS patients.
TNF ϭ tumor necrosis factor; IFN ϭ interferon; IL ϭ interleukin. perfectly in line with a previously published study in which active MRI lesion appearance seemed to be preceded by a decrease in circulating cytokineproducing T cells. 26 It should be noted here, however, that in this exploratory study, the observed alterations in immune measurements are relatively modest and that the p values indicate the significance of quadratic trends in the mean values over time, not necessarily that the mean values are significantly higher during autumn than during other seasons. Furthermore, it should be noted that the quadratic shape was not prespecified. Therefore, our p values need to be interpreted with caution.
Seasonal cycles of disease prevalence and immune function exist in avian and mammalian populations. 11 In wild populations of rodents, lymphatic organ size and immune function increase in the fall and winter and then decline in the spring and summer. 11 The effects of season on the immune system are considered to be an adaptive or survival mechanism to help animals cope with the more physiologically demanding winter environment (e.g., decreased temperature, increased energy needs, decreased food availability, and increased stress).
11
Seasonal rhythms can result both from cycles in immune competence and therefore susceptibility to disease and from differences in exposure to pathogenic organisms.
11 Viral infections are more common in particular seasons and have been shown to increase the relative risk for relapse.
14 Therefore, viral infection rates have been suggested as a possible explanation of the observed fluctuations of immunologic and radiologic effects in MS. 13, 17, 27 However, our patient group was not systematically studied for viral and other infections during the trial.
In our study, 30 of the 41 relapses were treated with IVMP. No significant differences between IVMP-treated and nontreated patients could be demonstrated, thus indicating that IVMP administration does not account for the seasonal variation in immune measurement changes. Furthermore, no significant differences could be demonstrated between patients with relapsing-remitting and secondary progressive MS. In addition, no differences were found between anti-CD4-and placebo-treated patients, as could be anticipated based on the results of the previously published analysis of this trial. 19 
